Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, randomized, investigator-blind trial to evaluate the bacteriologic eradication, safety and tolerability, and pharmacokinetics of different dosages of faropenem medoxomil BID for 10 Days in the treatment of acute otitis media

Next Previous
Trial Profile

Prospective, randomized, investigator-blind trial to evaluate the bacteriologic eradication, safety and tolerability, and pharmacokinetics of different dosages of faropenem medoxomil BID for 10 Days in the treatment of acute otitis media

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2008

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Faropenem medoxomil (Primary)
  • Indications Bacterial infections; Otitis media
  • Focus Therapeutic Use
  • Sponsors Cardiovascular Systems

Most Recent Events

  • 29 Mar 2007 Interim results have been reported.
  • 22 Dec 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top